Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Isotonic designs for phase I trials.

D H Leung1, Y Wang

  • 1Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. leung@biost.mskcc.org

Controlled Clinical Trials
|April 18, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Emergence of Elastography for Cystic Fibrosis Liver Disease.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2020
Same author

Urinary metabolomics reveals unique metabolic signatures in infants with cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2018
Same author

Reply to L'Huillier et al.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015
Same author

High prevalence of hepatitis B nonimmunity in vaccinated pediatric liver transplant recipients.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015
Same author

Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases.

Clinical cancer research : an official journal of the American Association for Cancer Research·2001
Same author

Is there a role for incomplete resection in the management of retroperitoneal liposarcomas?

Journal of the American College of Surgeons·2001

This study introduces a model-free approach for phase I cancer trials to find the maximum tolerable dose. The method improves upon standard cohort-based dose escalation by better estimating toxicity risks.

Area of Science:

  • Clinical Trials
  • Biostatistics
  • Pharmacology

Background:

  • Phase I cancer trials aim to identify the maximum tolerable dose (MTD) of novel therapeutics.
  • Current standard methods often rely on escalating doses in small patient cohorts.
  • Existing parametric approaches may not be suitable when dose-toxicity relationships are unknown or complex.

Purpose of the Study:

  • To propose a simple, model-free approach for phase I cancer clinical trials.
  • To enhance the determination of the maximum tolerable dose (MTD) without assuming a parametric dose-toxicity relationship.
  • To improve upon the widely used cohort-based dose escalation method.

Main Methods:

  • Modification of the standard cohort-based dose escalation method.
  • Assumption of a non-decreasing dose-toxicity relationship.

Related Experiment Videos

  • Application of isotonic regression to accumulated toxicity data.
  • Dose selection based on estimated toxicity closest to the target maximum tolerable toxicity.

    • Main Results:

    • Simulations demonstrate superior performance compared to the commonly used dose-escalation method.
    • The proposed model-free approach shows favorable comparisons with other existing phase I trial designs.
    • The method provides a robust alternative when parametric assumptions are undesirable.

    Conclusions:

    • The developed model-free isotonic regression approach offers an effective and statistically sound alternative for phase I cancer trial dose finding.
    • This method enhances the safety and efficiency of MTD determination.
    • It provides a valuable tool for clinical trial design in oncology.